Clinical Trial

Hexaware Launches CDAaaS in Partnership with PointCross Life Sciences

Platform Solution Helps Reduce Benchmarked Clinical Data Management Costs and Time Significantly ISELIN, N.J. and MUMBAI, India and LONDON, Sept. 24,…

4 months ago

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren’s Syndrome

Sjogren's Syndrome is a rare autoimmune disease with limited treatment optionsPrior U.S. Phase 3 data demonstrated benefitsSAN DIEGO, CA /…

4 months ago

Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds

Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

4 months ago

Sona Nanotech Closes Private Placement Financing to Raise $1,643,750 in Gross Proceeds

Halifax, Nova Scotia--(Newsfile Corp. - September 24, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona")…

4 months ago

Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide

Curium Opens New Lu-177 Production Facility, Transforming Cancer Treatment Curium project team with Kate Briant, Ciril Faia, Frank de Lange…

4 months ago

Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology – Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference

VANCOUVER, British Columbia, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the…

4 months ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Boehringer is advancing the development of SZN-413 to prepare it for potential future clinical testing SZN-413 is a bi-specific antibody…

4 months ago

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Oral Simufilam in On-going…

4 months ago

Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

4 months ago

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

Hamilton, Bermuda, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Company to host conference call today at 8.30 a.m. ETContinued progress within…

4 months ago